The first study from OHSU's new Oregon Stem Cell Center, published in the current issue of the journal Nature Medicine, found that mature macrophages derived from bone marrow stem cells, and not bone marrow stem cells themselves, are what fuse with diseased liver cells, ultimately curing a genetic liver disease.
"The most important discovery is you don't need to transplant stem cells at all," said study co-author Markus Grompe, M.D., professor of molecular and medical genetics, and pediatrics, OHSU School of Medicine, and director of the Oregon Stem Cell Center. "If you transplant only macrophages, you'll get liver cells that correct liver disease in mice."
Holger Willenbring, M.D., postdoctoral fellow of molecular and medical genetics, and the study's lead author, called fusion between macrophages and hepatocytes, the cells in the liver that provide the typical functions of this organ, "a rare physiological, but potentially therapeutically exploitable, phenomenon."
"Macrophages are known to fuse with themselves," Holger said. "Therefore, it is not absolutely surprising that they can fuse with other cells as well, especially, since macrophages physiologically reside in the liver and comprise a substantial fraction of the liver cells.
Usually, they participate in resolving inflammation, taking care of debris and producing factors that help the liver to function. In addition, they provide a link between the bone marrow compartment and highly specified organ cells, and this is new and exciting because of therapeutic implications."
The findings are the latest in a series of discoveries by Grompe's laboratory since 2000, when it first showed blood-forming stem cells derived from bone marrow, called hematopoietic stem cells, can cure liver disease in mice. It later found that the liver cells were corrected by cell fusion rather than differentiation of the transplanted stem cells.
"Various labs have reported that bone marrow or blood stem cells are like super cells. They can turn into anything - liver, lung, brain, muscle," Grompe said. "Our thought was that blood stem cells are really there to repair all tissues, and we showed that you can cure liver disease with blood stem cell transplantation.
"Then we found out that the bone marrow cells were not turning into liver cells directly, but that they were fusing with preexisting liver cells instead. In cell fusion, two distinct cells meld to form a single, new cell. The liver cells were turning the blood cells into their own kind."
In the latest study, macrophages derived from bone marrow stem cells were transplanted into the spleens of mice with the genetic liver disease fumarylacetoacetate hydrolase deficiency, also called hereditary tyrosinemia in humans. Each mouse was injected with 1 million macrophages. The spleen, upstream from the liver, slowly releases the macrophages into the liver, which would otherwise wash cells away in its blood-rich environs. The result was "robust production" of functional hepatocytes..
"This means you can get away with using only macrophages in transplantation," Grompe said. "For bone marrow transplantation, to get a stem cell transplant to work, you need to treat the host with lethal doses of preparative irradiation, which has severe side effects. Here we show this harsh treatment is not necessary for macrophages to turn into useful liver cells."
Willenbring said transplantation of macrophages or their immediate, short-lived progenitors is much more targeted toward treatment of damaged liver tissue than using whole stem cells from which they're derived.
The discovery "strongly argues against stem cell plasticity because you're not using stem cells at all," Grompe said. To be sure, his laboratory used macrophages exclusively in the transplantation and "it worked." Macrophages also can more easily be grown in tissue culture than stem cells, and future studies will even look at whether they can be genetically modified before transplantation.
"That's the future. That's what we're trying to do," he said.
As for stem cell plasticity, Grompe said he and his colleagues "just don't see it," at least in liver cell repopulation.
"That could mean two things: We're blind, or it doesn't happen," he said. "I think the burden of proof is now on the people doing that work, to show that what they're seeing is not fusion."
The study was funded by the National Institutes of Health.
To access all OHSU news releases, visit http://www.